Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021

More articles from Bench to Bedside

  • You have access
    Potential molecular therapy for acute renal failure
    H. David Humes, MD
    Cleveland Clinic Journal of Medicine March 1993, 60 (2) 166-168;

    As more is learned about renal epithelial cell regeneration and differentiation, exogenously administered growth promoters seem a likely intervention.

  • You have access
    Myasthenia gravis therapy: immunoadsorbent may eliminate need for plasma products
    Koji Sawada, MD, Paul S. Malchesky, DEng, Anna P. Koo, MD and Hiroshi Mitsumoto, MD
    Cleveland Clinic Journal of Medicine January 1993, 60 (1) 60-64;

    This new technique accomplished nearly complete removal of anti-acetylcholine receptor antibody with minimal loss of albumin.

  • You have access
    Cytokines and the pathogenesis of insulin-dependent diabetes mellitus
    Ben H. Brouhard, MD
    Cleveland Clinic Journal of Medicine November 1992, 59 (6) 629-633;
  • You have access
    Calcium-channel blocking agents as therapy for amphotericin B nephrotoxicity
    Ben H. Brouhard, MD and Barbara Baetz-Greenwalt, MD
    Cleveland Clinic Journal of Medicine May 1992, 59 (3) 263-264;

    Concomitant use of calcium-channel blockers may prevent nephrotoxicity and permit use of full therapeutic doses of amphotericin B in systemic fungal infection.

  • You have access
    Use of angiotensin-converting enzyme inhibitors in chronic progressive renal disease
    Kimberly C. Irwin, MD, Robert J. Cunningham, MD and Nicholas T. Stowe, PHD
    Cleveland Clinic Journal of Medicine March 1991, 58 (2) 184-190;

    In chronic renal disease, ACE inhibition may counteract certain changes that lead to end-stage renal failure.

  • You have access
    A new intracellular flush solution improves renal transplant preservation
    Peter N. Bretan, MD and Andrew C. Novick, MD
    Cleveland Clinic Journal of Medicine January 1991, 58 (1) 54-58;

    A new renal preservation flush solution minimizes the ischemic injury that occurs during hypothermic storage and reperfusion.

  • You have access
    Lipoprotein abnormalities in the progression of renal disease
    Michael D. Cressman, DO, Kimberly C. Irwin, MD and Nicholas T. Stowe, PhD
    Cleveland Clinic Journal of Medicine October 1990, 57 (7) 599-604;

    Animal models suggest that lipid-dowering agents may benefit patients with chronic progressive renal disease.

  • You have access
    New Series
    Ben H. Brouhard, MD
    Cleveland Clinic Journal of Medicine September 1990, 57 (6) 512;

    An innovative series will address issues in basic science that are relevant to the practice of medicine.

  • You have access
    Intra-arterial chemotherapy for brain tumors
    Samuel J. Hassenbusch, MD, PhD, James H. Anderson, PhD and Donald M. Whiting, MD
    Cleveland Clinic Journal of Medicine September 1990, 57 (6) 513-520;

    A program involving rabbit and human protocols demonstrates the successful integration of basic and clinical research with practical applications.

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire